CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).

[1] As of 2007 it was in phase II clinical trials for the treatment of depression.

[2] In 2013, work on the drug was terminated.

This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.